טוען...
Angiogenesis Inhibitors in NSCLC
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with a...
שמור ב:
| הוצא לאור ב: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5666703/ https://ncbi.nlm.nih.gov/pubmed/28934120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18102021 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|